- South Korea
- /
- Medical Equipment
- /
- KOSDAQ:A314930
Individual investors invested in Biodyne Co., Ltd. (KOSDAQ:314930) up 19% last week, insiders too were rewarded
Key Insights
- Significant control over Biodyne by individual investors implies that the general public has more power to influence management and governance-related decisions
- A total of 6 investors have a majority stake in the company with 43% ownership
- Insider ownership in Biodyne is 42%
A look at the shareholders of Biodyne Co., Ltd. (KOSDAQ:314930) can tell us which group is most powerful. The group holding the most number of shares in the company, around 57% to be precise, is individual investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
Following a 19% increase in the stock price last week, individual investors profited the most, but insiders who own 42% stock also stood to gain from the increase.
In the chart below, we zoom in on the different ownership groups of Biodyne.
See our latest analysis for Biodyne
What Does The Lack Of Institutional Ownership Tell Us About Biodyne?
We don't tend to see institutional investors holding stock of companies that are very risky, thinly traded, or very small. Though we do sometimes see large companies without institutions on the register, it's not particularly common.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company. Alternatively, there might be something about the company that has kept institutional investors away. Biodyne might not have the sort of past performance institutions are looking for, or perhaps they simply have not studied the business closely.
Hedge funds don't have many shares in Biodyne. The company's CEO Wook-bin Im is the largest shareholder with 42% of shares outstanding. For context, the second largest shareholder holds about 0.5% of the shares outstanding, followed by an ownership of 0.2% by the third-largest shareholder.
On studying our ownership data, we found that 6 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
Insider Ownership Of Biodyne
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
It seems insiders own a significant proportion of Biodyne Co., Ltd.. Insiders have a ₩199b stake in this ₩473b business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.
General Public Ownership
The general public, who are usually individual investors, hold a substantial 57% stake in Biodyne, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Biodyne you should know about.
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Valuation is complex, but we're here to simplify it.
Discover if Biodyne might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A314930
Biodyne
Develops and manufacturers medical devices, reagents, and consumables in South Korea.
Flawless balance sheet with minimal risk.
Market Insights
Community Narratives


